Clinical Trials Logo

Clinical Trial Summary

- Detection of primary antimicrobial susceptibility and resistance of Helicobacter Pylori infection. - Detection of resistance and virulence genes of Helicobacter Pylori infection. - Assessment of H pylori carcinogenicity gene. - Evaluation of outcome and efficacy of antibiotics regimen will be used in our research. - Evaluation of effect of other factors as diet (fatty and spicy meal), drugs as NSAIDs use, antibiotics for any cause on response of H pylori to antibiotics regimen.


Clinical Trial Description

Helicobacter pylori (H. pylori) infection is one of the most common infections in humans, affecting more than half of the world population. New infections are thought to occur as a consequence of direct human-to-human transmission or environmental contamination. The prevalence of the infection varies widely in rural developing areas (more than 80%) compared to urban developed ones (less than 40%), as a consequence of different socioeconomic and hygienic conditions . The vertical mode is infection spread from ascendant to descendent within the same family, while horizontal transmission involves contact with individuals outside the family or environmental contamination. Most individuals are infected by Helicobacter pylori during early childhood; in developing countries. Successful eradication is important to prevent the development of antibiotic resistance, as well as to reduce the number of treatments and procedures. Thus, national/ regional antibiotic resistance data could be used to guide treatment regimens for H pylori infection . Several clinical factors associated with increased rates of antibiotic resistant H. pylori, including history of previous antibiotic exposure, increasing age, female gender, ethnicity/race, extent of alcohol use, and non-ulcer dyspepsia . The primary antibiotic resistance of H. pylori is increasing worldwide. The overall resistance rate was found to be 4.55% for amoxicillin; 27.22% for clarithromycin; 39.66% for metronidazole; and 22.48% for levofloxacin. Therefore, drug susceptibility result of these antibiotics is necessary to select the appropriate drug for the successful eradication of the infection. Helicobacter pylori exhibit specific geographic distributions that are related to clinical outcomes. Despite the high infection rate of H. pylori throughout the world, the genetic epidemiology surveillance of H. pylori still needs to be improved. ;


Study Design


Related Conditions & MeSH terms


NCT number NCT05444439
Study type Interventional
Source Assiut University
Contact Nariman Zaghloul Bekhiet, Assistant lecturer
Phone 01021297091
Email narimandoctor@med.aun.edu.eg
Status Not yet recruiting
Phase N/A
Start date September 2022
Completion date October 2023

See also
  Status Clinical Trial Phase
Completed NCT03629587 - Helicobacter Pylori and it's Hematological Impact
Recruiting NCT03347513 - Eradication of H-pylori in Pregnancy and Its Effect on Iron Replacement Therapy? Phase 4
Completed NCT05680532 - The Improvement of Black Raspberry in Obese and Mild AZ Patients Infected With H. Pylori N/A
Recruiting NCT06275204 - H. Pylori Screen-and-treat Study in a Population of Young Adults
Completed NCT03857425 - Helicobacter Pylori Eradication With Clostridum Butyricum Capsule and Bacillus Coagulans Tablets Phase 4
Recruiting NCT03555526 - Genotypic Resistance Guided Therapy for Refractory H. Pylori Infection Phase 4
Not yet recruiting NCT05789550 - HELICOBACTER PYLORI INFECTION IN TYPE 2 DIABETES MELLITUS IN ASSIUT UNIVERSITY HOSPITAL
Not yet recruiting NCT03911791 - Screening of Helicobacter Pylori in Children of Positive Infected Mothers